0001104659-26-055318
SEC filingNuvectis Pharma reported wider Q1 FY2026 operating and net losses of -$6.3M (-12.4%) and -$6.0M (-13.5%) versus prior year, driven by higher R&D and G&A expenses, while diluted EPS improved to -$0.26 (3.7%) and cash burn accelerated to -$6.5M.
Nuvectis Pharma, Inc. (NVCT) reported GAAP operating income of -$6.3 million for the three months ended March 31, 2026, representing a 12.4% worsening from -$5.6 million in the prior-year quarter. This reflects the company's ongoing investment in its clinical-stage oncology pipeline, where all research and development costs are expensed as incurred. The broader operating loss highlights the capital-intensive nature of advancing pipeline candidates through preclinical and clinical stages, consistent with biotech development dynamics.
Net income followed a similar trajectory at -$6.0 million, 13.5% deeper than the -$5.3 million loss in Q1 FY2025. Diluted EPS showed relative resilience, improving to -$0.26 from -$0.27, a 3.7% enhancement driven by the interplay of loss expansion and changes in share count. Investors should note this EPS dynamic as it underscores how equity issuances via ATM and public offerings influence per-share metrics amid persistent losses.